
Product
CJC-1295 10mg w/ DAC
$120.00
CJC-1295 with DAC is a long-acting growth hormone releasing peptide designed to provide sustained release and longer activity compared to non-DAC versions. Ideal for research applications requiring extended duration and reduced administration frequency. For research use only. Not for human consumption
98 in stock
Shipping & Delivery Policy:
Due to high demand and periodic inventory replenishment from our overseas manufacturing partners, certain products may occasionally experience slight shipping delays. However, all orders are processed as quickly as possible, and customers can expect delivery within approximately 10–15 business days from the date the order is placed. If any unusual delay occurs beyond that timeframe, we will contact the customer directly with an update.
Product Description
Description
CJC-1295 (with DAC)
CJC-1295 with DAC is a long-acting growth hormone releasing peptide designed to support sustained growth hormone and IGF-1 release over time. The addition of DAC (Drug Affinity Complex) allows for a longer half-life compared to non-DAC versions, meaning fewer administrations are typically needed.
Key Features:
- Extended-release formula (longer half-life)
- Supports natural growth hormone stimulation
- Designed for research and laboratory use only
- Convenient dosing schedule compared to shorter-acting alternatives
What makes it different from CJC without DAC?
CJC-1295 with DAC stays active in the system longer, providing a more sustained release. Non-DAC versions are shorter acting and generally require more frequent administration.
Product Details:
- High-purity lyophilized peptide
- Securely sealed sterile vial
- For research purposes only — not for human consumption
If you have questions about this product, please contact us before purchase.
Important Notice:
This product is intended strictly for laboratory research purposes only. Not for human or veterinary consumption.
Learn more about our full line of Research Peptides.


Reviews
There are no reviews yet.